Global Processing Services Welcomes Three Independent Non-Executive Directors to Its Board
23.2.2023 08:00:00 EET | Business Wire | Press release
Global Processing Services (“GPS”), a fast-growing next-gen global payments technology platform, today announced the appointment of Paulette Rowe, Shane Happach, and Lynn McCreary as independent Non-Executive Directors.
Paulette Rowe is one of the most influential women in payments, recognised by American Banker in its annual honours list for three consecutive years, and was formerly CEO of Paysafe’s Integrated and Ecommerce Solutions (IES) division. Paulette brings a wealth of experience across card-based and virtual wallet payment solutions. Prior to Paysafe, Paulette was Head of Payments and Financial Services Partnerships for Facebook and held senior roles in a variety of financial organisations over a 20-year period, including Barclaycard, Royal Bank of Scotland (RBS), Tesco Bank, and GE Capital.
Shane Happach is an experienced global payments executive with strengths in enterprise sales and fintech-led disruption. Shane was recently named as CEO of Singapore-based fintech, Coda Payments. Prior to Coda, Shane was CEO of payments fintech Mollie for two years, and spent more than a decade at Worldpay, where he held a number of senior positions, including EVP, Head of Global Ecommerce and Chief Commercial Officer. Before Worldpay, he worked with GlobalCollect – acquired by Ingenico in 2014 – in business development roles across the Americas and EMEA.
Lynn McCreary brings over three decades of experience in legal, business and executive leadership roles to GPS, having worked at financial services and payments firm Fiserv for 11 years, serving as Chief Legal Officer since 2013. Her responsibilities at Fiserv included directing the firm’s global legal, ethical and compliance activities, as well as taking an active role in coordinating its M&A strategy. Prior to joining Fiserv, Lynn was an equity partner at Bryan Cave LLP, now Bryan Cave Lighton Paisner, where she represented the interests of financial services companies, insurance companies, retailers and others in a broad range of commercial disputes. Lynn is currently Chief Legal Officer of Sportradar.
“Paulette, Shane and Lynn bring a wealth of experience to our Board and will support our team to capitalise on the enormous potential for disruption in the issuer processing space,” said Gene Lockhart, Chair of GPS. “GPS is committed to investing for the long-term to support our clients in accelerating innovation, diversifying product capabilities and facilitating new payments programmes worldwide.”
GPS has attracted a number of highly experienced global payments executives under the leadership of Kevin Schultz as Chief Executive Officer since July 2022. The company most recently announced the appointment of Visa veteran Jim McCarthy as Executive Vice President – Global Product and Sales, who has more than 30 years of payments experience; Kevin Fox as Chief Revenue Officer, and Jeff Burns as Chief Financial Officer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005772/en/
Contact information
Louisa Bartoszek
Head of Communications, GPS
Louisa.bartoszek@globalprocessing.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom